Hi Everyone! Please post your questions here to the chat! 🖐

What questions did you ask the 150 researchers? How did you discover the problem of your customer?

Hello! AnalysisMode is a fascinating solution to help scientists! Could it possible to know what would be the data source for the AI? Is it only the answers from the scientists and how is the flexibility of the solution?

Question to Neurosalience: How do you compare against Combinostics?

good day everybody, sorry for being late. greetings from White Cross Emergency Estonia

What are your plans for expanding the executive team?

Another question for future discussions: What do the physicians do with the more accurate information, what is the health economic benefit?

Hi Ksenia. Assuming the doctors have info about early dementia in patients, what actionable items can they take given this info to help the patients?

Question: What classification are you going to be under MDR?

Got it from a slide, thanks! :D

Why can't a normal wearable handle this again?

Question to Henkaus: Should it be used for spot measurements, or continuous monitoring? Which has clinical significance? I know wearables are not there yet, but do you see that will pose significant competition over the next 3-5 years?

https://ouraring.com/

Dear startup teams! Please feel free to answer here the questions

that there was no time to answer to during the past 5 minutes 🙂

Hi Anna-Liisa. How did you assess efficacy compared to competitors? Also how do you think the cost of goods will compare to competitors?

Who from the current players in the wound care market is looking at this segment? Are you talking with them?

Hello Gleb! Our competitors are mainly big players whose solutions have aged. When we went to the hospitals to talk to doctors, it was clear that the problem is unsolved and patients want better treatments. We have talked to some big players and they would want to see the clinical data and for this we are aiming for at this stage.

Thank you.

Hello Rolf, the active ingredients are medicinal substances used in different medical devices. Our novelty is the combination of the polymers and the active ingredient formulation.

Questions to Dermtest:

- There ar every nicely performing image-based AI diagnostic tools for skin cancers and other conditions existing. What is new in your solution?

- There will be a lot of resistance from care teams to implement “another system” to manage their communication, workflows etc. How have you factored this in in your product development and/or go-to-market plans?

Answers to Marko:

Feel free to post your questions here 🖐

AI solutions just provide the initial diagnosis, but there is no point of giving an AI diagnosis to psoriasis patient, who has had the disease for 17 years, it doesn’t help them really. With skin cancer, you need a dermatoscope, as this is the gold standard (+30% accuracy compared to bare-eye). So this photo has to be made by clinician. But all in all, there is a place for AI, we plan to integrate the best ones as there are 1800 derm AI projects and companies world-wide out there - we are discussing with two. But we solve the harder part - exactly the second question. AI has to fit with the actual clinical process and I believe that we have found the right balance point there to capture the full care pathway. There is a simple to adopt solution as SaaS (docs understand the need with 1-2 minutes) and upsell functionalities, but for more complex models reimbursement approach is relevant (we have quite some experience and track record with this one). Insurances can motivate doctors (right incentives).

Is there any evidence that the combination of tools used by .Life has benefits on depression? If not how do you plan on figuring it out?

Maragus: have you considered Go-To-Market via psychotherapists or clinics instead of direct-to-end-user? How do you think that channel can impact your growth and what priority do you assign to this channel?

@Margus - great developments during past 9 months. How do you clarify if the patient has depression and how do deal with edge-cases?

@Margus. Do you plan on running a clinical study to test if it works?

To Kirill: We are considering also going to the market via therapists, coaches and different platforms that provide access to mental health specialists. I believe that we have to do both - directly approaching the users and work through professionals. Professionals help us with credibility and deeper feedback to the product, direct approach is helping us approach the mass user better. For 2022 I would prioritize partnerships with therapists over any mass market activity, in the beginning we need a lot of feedback and work through therapists is better for that.

@Margus 👏🏻

To Katrina: Thank you for the feedback :) Our patient necessarily does not need to have depression already. We suit much better for the potential cases, for the prevention and delay of the problems. If the person already has depression, we are rather the complement to the work of psychiatrists and psychologists, who help the person to get sufficiently on track again to start the recovery process. We are rather part of recovery for those people.

Question to Cardiomtec: What will clinicians do with your information, that they can’t do with information from comparable/competitor devices that you listed? What is the difference in clinical course of action, what is the health economic benefit?

To Leonidas: Yes, we definitely need to do clinical study as well. We aim for the cooperation with universities in order to use our application in scientific studies to both improve our product and algorithms and also get more scientific support to our activities. We hope to get there somewhere in 2nd half of 2022.

Thank you Margus. If you go that route it might be worth looking into DIGA in Germany if you haven’t for potential reimbursement

Thanks, Leonidas, for the hint.

Marko, They can review ECG morphological changes during daily activities indicative of CAD. With that information, they can order patients with diagnostic testing and initiate medication to avoid expensive invasive interventions.

1. Evidence2. Understand regulatory approval3. Story and plan to go beyond home market

1* give out the product for free to gather data for validation.

Took 1.5 years for Apple Watch's heart rate tracking feature to be approved in Japan. It normally requires testing a Japanese cohort first.

No revenue questions.

What is the path to revenue? Accounts to sell it to?

T1: TeamT2: TractionT3: Timing

T4: Thesis

How about T5? Technology :) Clear USP

Theranos

Don't do it.

https://en.wikipedia.org/wiki/Cost_overrun

https://en.wikipedia.org/wiki/Feature_creep

WE HAVE THE WINNERS 🥳

Announcing this shortly!

Next time I'd suggest to put your slides on full screen.

I could see your notes.

You are right. just missed that

Congratulations to the winners!👏🏻

Congratulations to all winners! And all the other companies also, you were awesome!

Great Job everyone. You are the best :)

Thank you!!

Well done and congratulations! Special thanks to Shin, Ed and Erki for interesting panel. Lot's to keep in mind.

Please feel free to contact me via email, phone or Linkedin!lauri.kuronen@healthcapitalhelsinki.fi+358 40 575 1847https://www.linkedin.com/in/laurikuronen/

Thanks everyone!

Thank you everyone!